EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

The association between acute kidney injury and Polymyxin B treatment: A retrospective cohort study

Long Wen iD, Xuefeng Yuan, Xiaohui Liu iD, Dixuan Jiang, Lihua Liu iD, Jiheng Liu iD

Science Progress · 2025

DOI: 10.1177/00368504251379362 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Science Progress, 2025. Verfasst von Long Wen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine,…. Hauptthemen laut MEDLINE: Polymyxin B, Anti-Bacterial Agents, Acute Kidney Injury. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Science and Health Joint Project of the Natural Science Foundation of Hunan Province, Natural Science Foundation of Hunan Province, the Project of Hunan Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This retrospective study aimed to analyse the impact of polymyxin B (PMB) on nephrotoxicity parameters and identify associated variables. Patients and methods The study, which was conducted at a tertiary general hospital in China, included 84 patients over the age of 18 who had received PMB for a period of more than 48 h. Patients were divided into two groups based on the presence or absence of acute kidney injury (AKI) according to KDIGO standards. The identification of risk factors for PMB–associated AKI was facilitated by data collection and multivariate logistic regression analysis.

Results

The majority of patients were male, with a median age of 80 years (interquartile range (IQR): 68.5, 87.0) and a median weight of 60.0 kg (IQR: 50.0, 65.0). PMB was administered with a median loading dose of 1.73 mg/kg (IQR: 1.67, 1.82) and a median daily maintenance dose of 1.82 mg/kg (IQR: 1.67, 2.22) over a median treatment duration of 7.75 days (IQR: 5.00, 10.38). The development of AKI was observed in 36 patients (42.9%), with a median time to onset of 5 days (IQR: 3, 6). In the cohort of patients who developed AKI, 11 (30.6%) patients discontinued PMB therapy, while 8 (16.7%) patients required renal replacement therapy (RRT). The study revealed that concurrent chronic kidney disease (CKD) (odds ratio (OR) = 5.47, 95% confidence interval (CI) 1.52–19.64, P = 0.01) and the daily maintenance dose (OR = 12.57, 95% CI 2.84–55.59, P = 0.00) were independently associated with AKI onset following PMB therapy.

Conclusions

The potential association between PMB therapy and AKI raises clinical concern. Concurrent CKD and higher PMB maintenance doses were identified as independent risk factors for AKI associated with PMB therapy. Consequently, rigorous monitoring of renal function indices and therapeutic drug concentrations is recommended to facilitate early detection of nephrotoxic risks, thereby minimizing renal injury and ensuring the safe administration of PMB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyxin BAnti-Bacterial AgentsAcute Kidney InjuryRetrospective StudiesCohort StudiesHumansMaleAgedAged, 80 and overMultivariate AnalysisLogistic ModelsRisk FactorsGram-Negative Bacterial Infections

Stichwörter der Autor:innen

Polymyxin Bacute kidney injurydrug safetylogistic regression modelrisk factor

Substanzen

Polymyxin BAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of Chin…
  • Department of Nosocomial Infection Management, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China.
  • Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China.
  • Department of Pharmacy, The Third Hospital of Changsha, The Affiliated Changsha Hospital of Hunan University, Changsha, Hunan, People's Republic of China.
  • Department of Hematology & Oncology, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, PR China.

ORCID-Profile: Long Wen, Xiaohui Liu, Lihua Liu, Jiheng Liu

Förderung

  • the Science and Health Joint Project of the Natural Science Foundation of Hunan Province
  • Natural Science Foundation of Hunan Province
  • the Project of Hunan Provincial Health Commission

Zitieren

APA

Wen, L., Yuan, X., Liu, X., Jiang, D., Liu, L., & Liu, J. (2025). The association between acute kidney injury and Polymyxin B treatment: A retrospective cohort study. Science Progress. https://doi.org/10.1177/00368504251379362

Vancouver

Wen L, Yuan X, Liu X, Jiang D, Liu L, Liu J. The association between acute kidney injury and Polymyxin B treatment: A retrospective cohort study. Science Progress. 2025. doi:10.1177/00368504251379362

BibTeX
@article{Wen2025,
  author = {Wen, Long and Yuan, Xuefeng and Liu, Xiaohui and Jiang, Dixuan and Liu, Lihua and Liu, Jiheng},
  title = {The association between acute kidney injury and Polymyxin B treatment: A retrospective cohort study},
  journal = {Science Progress},
  year = {2025},
  doi = {10.1177/00368504251379362}
}
Kostenlos starten →